Retrogenix has identified several novel immune checkpoint targets that are now the focus for the development of exciting new immunotherapies.
Identifying new immunotherapy targets provides significant commercial value for our clients as well as uncovering the mechanisms of action that broadens our overall understanding of how cancer cells avoid triggering an immune response.
Cancer can evade immune detection by ‘switching off’ T-cells through inhibitory ligand-receptor interactions at immune checkpoints. Antibodies or recombinant forms of receptors or ligands that disrupt these interactions can stimulate very effective anti-tumour responses. Recent discoveries in this area have significantly expanded the range of therapies that are being developed for patients, with the ultimate aim of conferring long-term immunity to cancer.
Retrogenix’s results are included in multiple patent applications that have been made by our study sponsors in order to protect the valuable intellectual property that has arisen from these key discoveries. As many important immune checkpoint interactions are still yet to be fully characterised we continue to work extensively in this area. Our case studies below demonstrate how the cell microarray technology is used to identify immune checkpoint targets with a high degree of specificity.
Contact us to discuss an immune checkpoint project with a member of our science team.